Investigational Device Exemption IDE

Related by string. * investigational : investigational compound . investigational compounds . Investigational Device Exemption / DEVICE . DEVICES . devices : Advanced Micro Devices . California Micro Devices . improvised explosive device / Exemptions . EXEMPTION . exemptions : sponsor exemption . antitrust exemption . applicable exemption therefrom / Ide . Ides : Java IDE . Actel Libero IDE * *

Related by context. All words. (Click for frequent words.) 79 Investigational Device Exemption 72 Premarket Approval PMA 72 exemption IDE 66 Market Approval PMA 66 Phase III pivotal 66 Augment Injectable 65 liver resection surgeries 65 Phase 2b clinical 65 Phase 2a clinical 65 Phase IIIb clinical 65 pivotal Phase III 64 Phase IIb 64 Pivotal Clinical Trial 64 Phase 2a 64 Phase III clinical 63 Pivotal Trial 63 IND Investigational New 63 phase IIb clinical 63 multicenter clinical 63 phase IIa clinical 63 randomized controlled Phase 63 Investigational 63 Augment Bone Graft 62 ORBIT II 62 OLpur TM H2H 62 Phase IIa trial 62 Marketing Authorization Application 62 REPEL CV 62 FDA Approvable Letter 62 Marketing Authorization Application MAA 62 Exemption IDE approval 62 Drug Eluting Stent System 62 Luveniq 62 confirmatory Phase 3 62 BLA submission 62 investigational 62 Premarket Approval Application 62 FDA Investigational Device 62 TAXUS Element Paclitaxel Eluting 62 Phase 2b study 62 FOLOTYN ® 62 Biologic License Application BLA 61 CIP TRAMADOL ER 61 Phase IIb clinical 61 Marketing Authorisation Application 61 placebo controlled Phase III 61 multicenter Phase 61 Phase IIb III 61 PROPEL trial 61 rALLy clinical trial 61 Phase 2b kidney transplant 61 Dupuytren Contracture 61 phase IIb trial 61 Premarket Approval 61 Cloretazine ® 61 Phase IIa 60 PROMUS Element Stent 60 Phase #b/#a clinical 60 TAXUS Element Stent System 60 PMA submission 60 ongoing Phase 1b 60 Phase 2b trial 60 Pivotal Phase III 60 Phase III 60 New Drug IND 60 Cellegesic 60 PFO migraine 60 pivotal Phase 60 Biologics License Application BLA 60 PDX pralatrexate 60 randomized controlled multicenter 60 drug eluting coronary stent 60 Phase III Clinical Trial 60 Biologics License Application 60 Phase Ib study 60 ADVANCE PD 60 Phase IIIb 60 BRIM2 60 ThermoDox R 60 MIST II 60 phase Ib clinical 60 Phase IIb kidney transplant 60 Phase IIIb study 60 Phase Ib 60 SUCCEED trial 60 Phase IIa clinical 60 BrachySil 60 phase IIa 59 IND submission 59 Lymphoseek ® 59 PrevOnco 59 sNDA submission 59 Neo Urinary Conduit 59 Civacir 59 Government Qualifying Therapeutic 59 BioSTAR R 59 GEM OS1 59 Phase Ib clinical 59 TM Drug Eluting 59 Anturol TM 59 Phase 2a trial 59 PROTECT AF 59 Fast Track Designation 59 dose escalation clinical 59 multicenter Phase II 59 COMFORT II 59 Phase Ib II 59 Phase 2b 59 APEX PD 59 trastuzumab DM1 T DM1 59 Iluvien ® 59 Application BLA 59 Bone Graft 59 Phase III clinical trials 59 EOquin TM 59 European Sepsis Trial 59 PROVENGE sipuleucel T 59 PROGENSA R 59 vertebral augmentation 59 CORTOSS 59 COSIRA trial 59 Aurexis 59 Pivotal Study 59 BST CarGel R 59 Orphan Drug status 59 Completes Patient Enrollment 59 PrevOnco ™ 59 placebo controlled Phase 59 Trobalt 59 phase Ib 59 MONOVISC 58 Phase Ib IIa 58 registrational 58 ENLIGHT 58 Eluting Coronary Stent System 58 ENDEAVOR IV 58 PROMUS Element Everolimus Eluting 58 CryoSeal FS System 58 MelaFind ® 58 Neovasc Reducer 58 Omigard 58 Phase 1b clinical 58 Biologic License Application 58 Humanitarian Device Exemption 58 Phase IIB 58 Diabetic Macular Edema 58 granted Ortec 58 BLA filing 58 Phase II 58 phase IIb study 58 Phase IIb trial 58 Granted Orphan Drug 58 multicenter Phase III 58 Phase III Pivotal 58 Alair System 58 MelaFind R 58 Orphan Drug Status 58 randomized Phase IIb 58 relapsed refractory multiple myeloma 58 IDE Investigational Device Exemption 58 Soliris eculizumab 58 Tarceva TM 58 miconazole Lauriad R 58 eSVS MESH 58 Phase lll 58 Prospective Randomized 58 IIa trial 58 phase 2a 58 TM Everolimus Eluting 58 XIENCE V Stent System 58 randomized Phase 58 Feasibility Trial 58 Special Protocol Assessment 58 lucinactant 58 Phase IIa trials 58 anticancer compound 58 metastatic castrate resistant 58 Patient Enrollment 58 PROMUS TM 58 RIGScan ™ 58 Urocidin 58 ThermoDox ® 58 Phase III psoriasis 58 Voraxaze 58 application sNDA 58 Dose Ranging Study 58 Personalized Immunotherapy 58 confirmatory Phase III 57 New Drug Application 57 urethral bulking agent 57 Metricath Gemini 57 Phase IIb clinical trials 57 CINTREDEKIN BESUDOTOX 57 Phase III confirmatory 57 Augment Injectable Bone Graft 57 NDA Submission 57 Facet Solutions 57 BioSTAR ® 57 Nabi HB Intravenous 57 oral ridaforolimus 57 PROMUS R 57 phase IIb 57 Combidex 57 PROVENGE ® 57 pivotal bioequivalence 57 ENDEAVOR III 57 R bendamustine hydrochloride 57 TG MV 57 Drug Submission 57 IL# PE#QQR 57 Fast Track Status 57 investigational humanized monoclonal antibody 57 Augment ™ Bone Graft 57 Clinical Trial Application 57 OrCel ® 57 Phase 1b clinical trials 57 Ereska 57 CUSTOM III 57 hoFH 57 OAB overactive bladder 57 ATryn R 57 Marketing Authorisation Application MAA 57 Iluvien TM 57 Zenvia Phase III 57 Axxion TM 57 Phase 1b trial 57 Amrubicin 57 REVIVE Diabetes 57 Phase III metastatic melanoma 57 Zelrix 57 Premarket Notification 57 GTC recombinant human 57 investigational pan BCR 57 TAXUS Liberte 57 registrational trial 57 CRMD# 57 ILUVIEN ® 57 EFAPROXYN 57 PHX# 57 pharmacokinetic PK study 57 IMPACT IMmunotherapy 57 confirmatory Phase 57 Onrigin 57 Endeavor drug eluting 57 Phase 1a clinical 57 Sirolimus eluting Coronary Stent 57 Phase 1b 57 FAME Study 57 supplemental Biologics License Application 57 Onalta ™ 57 Oral Calcitonin 57 Orathecin 57 EchoCRT 57 Combination REOLYSIN R 57 intravitreal insert 57 MIVI III 57 XIENCE V Everolimus Eluting 57 Medtronic CoreValve ® 57 Phase III multicenter 57 Vascular Wrap TM 57 GTC recombinant form 57 Prochymal TM 57 prospective randomized multicenter 57 II Clinical Trial 57 LymphoStat B TM 57 PANVAC VF 57 CoAxia 57 ExAblate R 57 tiapamil 56 CoreValve System 56 Pirfenidone 56 Ozurdex 56 paclitaxel eluting 56 Phase Ia 56 Vascular Wrap 56 immunotherapeutic vaccine 56 Arzerra ofatumumab 56 Files Investigational 56 Phase IIb Trial 56 investigational antiplatelet agent 56 Initiated Phase 56 Lung Rx 56 prospective multicenter 56 Matrix Phase 2b 56 apaziquone 56 NDA submission 56 label multicenter 56 ™ Paclitaxel Eluting 56 alvimopan 56 Adhesion Barrier 56 LUVENIQ 56 Dyloject TM 56 Phase Ib clinical trials 56 RANK Ligand inhibitor 56 OrCel R 56 VNP#M 56 Aryplase 56 Panzem R 56 refractory chronic lymphocytic 56 virus HCV protease inhibitor 56 Liberte TM 56 IMPACT DCM clinical 56 lorcaserin Phase 56 ELACYT 56 MAGE A3 ASCI 56 CIP Fenofibrate 56 iChem VELOCITY 56 Genasense ® 56 IONSYS TM 56 clinical trial 56 vapreotide acetate 56 Phase 2b Clinical Trial 56 Phase III Clinical Trials 56 Cellegesic TM nitroglycerin ointment 56 lomitapide 56 Levacor 56 Completes Enrollment 56 PROMUS Element 56 Fibrin Pad 56 MAA submission 56 fully bioabsorbable 56 CIP ISOTRETINOIN 56 Ceplene ® histamine dihydrochloride 56 Rhucin ® recombinant 56 acyclovir Lauriad R 56 induced macular edema 56 Troxatyl 56 Phase III randomized controlled 56 MEND CABG II 56 Receives Orphan Drug Designation 56 histamine dihydrochloride 56 Diabetic Macular Edema DME 56 Targretin capsules 56 Phase 2b clinical trials 56 LibiGel Phase III 56 Microcyn Technology 56 REG1 Anticoagulation System 56 RESTORE CLI trial 56 DC Bead 56 NeuroFlo 56 Junovan TM 56 lexidronam injection 56 Pivotal Phase 56 perifosine KRX 56 Ganite ® 56 received CE Conformite 56 EmbraceAC 56 Stent System 56 ABL inhibitor 56 Left Atrial Appendage 56 DEEP AF 56 multicenter phase 56 pralatrexate injection 56 eprodisate KIACTA TM 56 phase IIIb 56 delivers fluocinolone acetonide FA 56 Initiates Phase II 56 Zenvia ™ 56 CardioFit 56 Ventricular Assist System 56 Novolimus 56 IIb clinical trial 56 FDA Clearance 56 Sonatherm 56 Phase #b/#a 56 LUMINATE 56 PROMUS Element Stent System 56 Emboshield 56 coflex 56 autologous cellular immunotherapy 56 severe hypercholesterolemia 56 ™ Everolimus Eluting 56 stent DES 56 Myocet 55 dose escalation trial 55 Endeavor Drug Eluting 55 UPLYSO 55 SEPET TM 55 arsenic trioxide injection 55 reslizumab 55 HepaSphere 55 Submits Investigational 55 dose escalation Phase 55 octreotide implant 55 LEUKINE 55 Dual Opioid 55 FIRAZYR 55 rolling Biologics License 55 Emezine 55 LUCASSIN 55 Initiate Phase 55 BLOOM DM 55 Initiate Clinical Trial 55 PERSEUS 55 Study Evaluating 55 IMA# 55 IMPACT DCM trial 55 Endurant 55 V Everolimus Eluting Coronary 55 BrachySil TM 55 Soliris TM eculizumab 55 drug eluting stent DES 55 Clinical Study 55 Augment ™ 55 Teysuno 55 Raptiva R 55 prospective multicenter randomized 55 Medidur TM FA 55 Locteron ® 55 Initiates Enrollment 55 Fast Track designation 55 Xcytrin R 55 exocrine pancreatic insufficiency EPI 55 Meets Primary Endpoint 55 Sonolith i move 55 severe gastroparesis 55 Accelerated Partial Breast Irradiation 55 Orphan Drug designation 55 Alvesco R 55 BR.# 55 MEND CABG 55 cetrorelix pamoate 55 ThromCat 55 INSPIRE Trial Phase III 55 Tramiprosate ALZHEMED TM 55 Phase #/#a 55 MOZOBIL 55 vernakalant hydrochloride 55 ruxolitinib 55 phase IIb III 55 EVEREST II 55 ENRICH trial 55 GATTEX TM 55 PREOS 55 Orphan Status 55 rALLy trial 55 CLARITY study 55 ZEVALIN ® 55 LEVADEX ™ 55 IgG1 monoclonal antibody 55 WX UK1 55 Aflibercept 55 BRIM3 55 injectable enzyme 55 TAXUS TM 55 FACTIVE R gemifloxacin 55 oral prodrug 55 randomized Phase III 55 CORTOSS Bone Augmentation Material 55 thorough QT 55 sodium Injection 55 phase III isavuconazole 55 Virulizin R 55 Efficacy Results 55 PREOS R 55 SPIRIT FIRST 55 doxorubicin Transdrug ® 55 Degarelix 55 Inc. OTCBB SYBD 55 Complete Response 55 Custom NX 55 placebo controlled clinical 55 Bazedoxifene 55 IIa clinical trial 55 Cypher Sirolimus 55 Kynapid 55 SNT MC# 55 QNEXA 55 injectable formulation 55 initiated Phase Ib 55 FDA Accepts 55 cyclobenzaprine hydrochloride extended 55 Ixempra 55 oral formulation 55 AIR CF1 55 k clearance 55 intravesical infusion therapy 55 Resten NG 55 VALSTAR 55 SYCREST 55 NASDAQ CLSN 55 Fodosine 55 Vitrasert R 55 Arzerra TM 55 ATryn ® 55 anterior lumbar interbody fusion 55 DASISION 55 diabetic macular edema DME 55 Xcellerated T Cells 55 Clinical Trial Evaluating 55 IND Filing 55 Cerepro ® 55 Zenvia TM 55 SpideRX 55 Crofelemer budesonide foam 55 acetonide FA 55 Pixuvri 55 Elagolix 55 Frova ® 55 nasal calcitonin product 55 MyVax R 55 Daclizumab 55 Cimzia TM 55 dasatinib Sprycel ® 55 intravenous formulation 55 Phase IIb Clinical Trial 55 assessing T DM1 54 BLP# Liposome Vaccine 54 FRDA 54 unique alkylating agent 54 RHEO 54 Self Expanding Stent 54 intravenous acetaminophen 54 Application MAA 54 OvaRex ® MAb 54 REVLIMID lenalidomide 54 Investigational Treatment 54 Medtronic CoreValve 54 Retacrit 54 Oxiplex 54 Embolic Protection Device 54 histone deacetylase HDAC inhibitor 54 PNP inhibitor 54 CALGB # [002] 54 Cardiac Cryoablation System 54 ferumoxytol Injection 54 hypoxia activated prodrug 54 pseudobulbar affect PBA 54 pralatrexate injection folate analogue 54 Generx ™ 54 Fibrin Sealant 54 PDE4 inhibitor 54 Dacogen injection 54 OLpur TM MD 54 AFRS TM 54 Loramyc R 54 mitogen activated ERK kinase 54 pain palliation 54 subcutaneous formulation 54 liposomal formulation 54 Genasense ® oblimersen 54 Marqibo 54 Phase III Trial 54 ATL# [001] 54 investigational compound 54 neratinib 54 Icatibant 54 initiate Phase IIb 54 treat atrial flutter 54 NP2 Enkephalin 54 FDA approvable letter 54 Plenaxis TM 54 Augment TM 54 AeroLEF TM 54 rilonacept 54 POSIDUR TM 54 forodesine 54 huC# DM4 54 FlowCardia 54 SANVAR 54 ofatumumab HuMax CD# 54 IND Application 54 BRILINTA 54 PROMACTA 54 evaluating tivozanib 54 Patient Enrolment 54 Iluvien 54 personalized cellular immunotherapy 54 LibiGel ® 54 ACUROX 54 OZURDEX ® 54 CLIA waiver 54 Release Capsules 54 Européenne Mark 54 CE Marked 54 Levacor VAD 54 single injection viscosupplement 54 double blinded placebo 54 relapsed multiple myeloma 54 registrational Phase 54 Ceflatonin 54 Receives Approvable Letter 54 Marketing Approval PMA 54 Initiates Phase III 54 prGCD 54 catheter occlusion 54 VIVITROL ® 54 oxybutynin ATD TM 54 LIALDA 54 label dose escalation 54 Proellex TM 54 Azedra 54 EP #R 54 sBLA 54 Levoleucovorin 54 blinded randomized placebo controlled 54 myoblast therapy 54 Vimpat ® lacosamide 54 STARFlex R 54 PI3K/Akt pathway inhibitor 54 velafermin belinostat 54 balsalazide tablet 54 Novacor LVAS 54 StemEx 54 CLIRS trial 54 randomized Phase 2b 54 k premarket 54 Ablation System 54 relapsing multiple sclerosis 54 NEVO TM 54 GLP1 INT TM 54 Cutanea Life Sciences 54 fosbretabulin 54 Cethrin 54 RIGScan 54 ABSORB trial 54 eluting stent 54 branded Rectogesic 54 topically applied SEPA 54 LVAS 54 peginesatide 54 IMPACT DCM 54 TRANSDUR Sufentanil 54 Ceflatonin ® 54 docetaxel Taxotere R 54 PRECISE trial 54 systemic anaplastic large 54 ARRY # 54 IV acetaminophen 54 Onco TCS 54 Supplemental Biologics License Application 54 omega interferon 54 Phase III HEAT 54 Prostate AdenoCarcinoma Treatment 54 PLK1 SNALP 54 rasagiline tablets 54 Commences Phase 54 ProEthic Pharmaceuticals 54 metastatic hormone refractory 54 Proxinium TM 54 EOS NASDAQ MELA 54 sulodexide 54 oral iron chelator 54 Yondelis ® 54 Phase 1a 54 GEM OS2 54 PMA Supplement 54 Restanza 54 Qutenza TM 54 Clinical Trial Results 54 dalbavancin 54 generation rotary VAD 54 Rhucin R 54 novel oral anticoagulant 54 Besivance 54 PROSTVAC ® 54 DuraHeart 54 NexStent 54 ARIKACE 54 supplemental biologics 54 Phase 2b randomized 54 Microplasmin 54 ACOMPLIA R 54 EOquin 54 teduglutide 54 mertansine 54 randomized multicenter 54 Cloretazine R VNP#M 54 compound CIP FENOFIBRATE 54 PRECISE Trial 54 STARFlex 54 NYSE Amex PTN 54 refractory metastatic colorectal cancer 54 Chemophase 54 NUEDEXTA ™ 54 registrational studies 53 Cordis Cypher 53 T Pred 53 RSD# 53 SYNERGY Stent 53 Randomized Phase II 53 Oracea TM 53 Hexvix 53 ATryn ® GTC recombinant 53 Curaxin CBLC# 53 biliary tract cancer 53 ADVEXIN p# therapy 53 Alzhemed TM 53 budesonide foam 53 FDA Premarket Approval 53 immunosuppressive compound 53 TELCYTA 53 CONBRIZA 53 Stabilimax 53 Telavancin 53 novel histone deacetylase 53 GENTAMICIN SURGICAL IMPLANT 53 StemEx R 53 NADiA ProsVue 53 investigational drug 53 Powerlink ® 53 OvaDx 53 OPT CHF 53 BrachySil ™ 53 sNDAs 53 Cleviprex TM clevidipine 53 relapsing remitting MS RRMS 53 SinuNase TM 53 Phase IIa clinical trials 53 Achieves Primary Endpoint 53 radiation sensitizer 53 KYNAPID 53 CVac 53 Levacor TM 53 oral rivaroxaban 53 Evoltra 53 VITAL Trial 53 candidates Augment ™ 53 Ketotransdel 53 Biological License Application 53 Corlux 53 EvaMist TM 53 EVICEL 53 LHRH antagonist 53 Nasdaq PGNX today 53 ThermoDox 53 Randomized Phase 53 Prestara 53 Nipent R 53 DURIN TM 53 pharmacokinetic PK 53 Clinical Trials Agreement 53 interferon gamma 1b 53 Pennsaid R 53 Certican 53 Veronate 53 RELISTOR ® 53 EXPAREL ™ 53 multicenter randomized controlled 53 PROTEGE 53 Nasdaq SPNC 53 Phase III Psoriasis 53 Bayer HealthCare Onyx Pharmaceuticals 53 Therapy Evaluation 53 alemtuzumab Campath 53 RSR# 53 Orthopedic Advisory Panel 53 Vicinium TM 53 ISENTRESS raltegravir 53 candidate XP# 53 alvespimycin 53 mechanical thrombectomy 53 Neo Bladder Augment 53 IND enabling 53 LensAR Laser System 53 inhaled formulation 53 Metformin GR 53 LEVADEX TM 53 PERSEUS clinical program 53 HoFH 53 Paradis Vaso Shield 53 NEVO 53 buccal insulin spray 53 methylnaltrexone bromide 53 crizotinib PF # 53 compound INCB# 53 methylnaltrexone 53 mTOR inhibitor 53 TEMSO 53 metastatic HRPC 53 Acute Radiation Syndrome ARS 53 ULTRASE 53 Phase IIB clinical 53 antibody MAb 53 Hedgehog Pathway Inhibitor 53 orphan designation 53 AVASTIN 53 Thalidomide Pharmion 53 HeartMate R 53 candidates Dyloject TM 53 ibuprofen Injection 53 PRESEPT 53 lorvotuzumab mertansine 53 cancer neuroendocrine tumor 53 TAXUS ATLAS 53 DAPT Study 53 OsseoFix 53 AVERROES 53 adjuvant GIST 53 Phase IIa Clinical Trial 53 Xcelerant Delivery System 53 PHASE III 53 Traficet EN 53 NasdaqGM NTEC today 53 Vascular Closure Device 53 Tezampanel 53 PREVAIL 53 Destination Therapy 53 TLK# 53 Oracea R 53 mesylate tablets approved 53 CryoCor Cardiac Cryoablation System 53 Tanespimycin 53 dependent kinase inhibitor 53 HGS# 53 Fibrillex TM 53 Telatinib 53 tramiprosate Alzhemed TM 53 Fx #A 53 Valtropin 53 PERLANE 53 BAY #-# 53 oral picoplatin 53 TURBO Booster 53 DermTech International 53 miconazole Lauriad ® 53 NEUMUNE 53 Intermezzo ® NDA 53 Ceflatonin R 53 ospemifene 53 ACAPODENE 53 Genasense R 53 Phase 2b Trial 53 molecular imaging radiopharmaceutical 53 SUPPRELIN R LA 53 ENTEREG ® 53 AVADO 53 ALN VSP Phase 53 Glatiramer Acetate 53 Genasense R oblimersen 53 successfully commercialize Iluvien 53 cell lymphoma CTCL 53 Junovan 53 Long Term Efficacy 53 PillCam COLON 53 Alocrest 53 Evoltra TM 53 miconazole Lauriad 53 OncoVEX GM CSF 53 Neuromodulation System 53 balsalazide disodium 53 refractory Hodgkin lymphoma 53 Ablation Frontiers 53 PFO closure 53 Treatment IND 53 NASDAQ OSIR 53 GLP toxicology studies 53 HCV protease inhibitor 53 NEBIDO R 53 Phase III placebo controlled 53 Demonstrates Sustained 53 OvaRex R 53 Clinical Trial 53 Accelerated Approval 53 Anturol ® 53 Visian Toric ICL 53 Cimzia ® certolizumab pegol 53 VBLOC 53 GALNS 53 PREVU * POC 53 GAMMAGARD 53 Oncobionic 53 visit www.dobimedical.com 53 SIR Spheres 53 Sorafenib HCC Assessment 53 ZACTIMA 53 Safinamide 53 recurrent glioblastoma multiforme 53 GATTEX ® 53 evaluating carfilzomib 53 SOLTAMOX TM tamoxifen citrate 53 CIMZIA TM 53 Wound Dressing 53 proprietary transdermal patch 53 APPRAISE 53 Phase III randomized 53 PROMUS Stent 53 Successfully Completes Phase 53 Pharos Vitesse 53 AIR CF2 53 GRAS notification 53 BioNumerik 53 Orazol 53 Uvidem 53 TORISEL 53 sNDA 53 multicenter randomized clinical 53 dose escalation phase 53 herpetic keratitis 53 Files IND 53 Presents Positive 53 Ganite R 53 rNAPc2 53 drug ISA# 53 granulated mesalamine 53 OMP #R# 53 Delcath Phase III 53 PATHFINDER R 53 label Lipofen R 53 Trofex 53 TAXUS Liberte stent 53 StaphVAX R 53 Market Authorization Application 53 Friedreich Ataxia FRDA 52 TRISENOX ® 52 APEX AMI trial 52 multicenter randomized Phase 52 RE COVER 52 multicenter randomized placebo controlled 52 Investigational Device 52 Phase 2a Clinical Trial 52 HuMax TAC 52 oxymorphone ER 52 MERLIN TIMI 52 Testosterone MDTS ® 52 Tarsa Therapeutics 52 Biomerix Corporation 52 Probuphine 52 Cytori Therapeutics NASDAQ CYTX 52 Expanded Indication 52 ORENCIA ® 52 brivaracetam 52 faropenem medoxomil 52 Safe GRAS status 52 Kamada AAT 52 GEM #S 52 targeted radiotherapeutic 52 NCIC CTG 52 Prodarsan 52 Orqis Medical 52 ORE# 52 iFuse Implant System 52 Onsolis 52 AQ4N 52 Symphony tCGM System 52 Phase IIb trials 52 Completes Patient Enrolment 52 evaluating nimotuzumab 52 omacetaxine mepesuccinate 52 oral deforolimus 52 ABRAXANE TM 52 Initiates Clinical Trial 52 multicentre randomized 52 topical formulation 52 QLT# 52 Rheos System 52 Androxal TM 52 indiplon capsules 52 RECOTHROM R 52 Raptiva ® 52 Phase #b/#a trial 52 PRIMO CABG 52 opioid induced bowel dysfunction 52 Trial Evaluating 52 Initiates Clinical 52 CIMZIA r 52 DuraHeart TM 52 vinorelbine tartrate 52 Oxycyte ® 52 product platforms AZX# 52 Gabapentin GR 52 recurrent malignant glioma 52 TM pralatrexate injection 52 ABRAXANE ® 52 AIR2 Trial 52 STEDESA 52 rALLy 52 FavId 52 Orphan Drug designations 52 Gliadel Wafer 52 PRECISE 52 candidate AP# 52 Preos 52 dose cohort 52 ZYBRESTAT TM 52 BiovaxID TM 52 acute peripheral arterial 52 iloprost Inhalation Solution 52 TEMODAL 52 MEK inhibitor RDEA# 52 Metastatic Melanoma 52 Urocortin 2 52 GetGoal Phase III 52 Tesamorelin 52 Pafuramidine 52 BioGlue R 52 PSMA ADC 52 RX ACCULINK 52 refractory cutaneous T 52 icatibant 52 SonoLysis 52 ACCEDE 52 Hsp# Inhibitor 52 ILUVIEN 52 EVIZON TM 52 sumatriptan DosePro 52 k Premarket Notification 52 Altropane 52 Iloperidone

Back to home page